Table 2.
Instances of toxicities possibly, probably, or definitely attributed to combined chemotherapy and oregovomab (N=9).
| Adverse Event | Grades 1– 2 | Grade 3 | Grade 4 |
|---|---|---|---|
| Hematologic | |||
| Anemia | 0 | 2 | 0 |
| Leukopenia | 0 | 3 | 3 |
| Thrombocytopenia | 0 | 4 | 0 |
| Lymphopenia | 0 | 4 | 0 |
| Reduced ANC | 0 | 2 | 4 |
| Non-hematologic | |||
| Nausea | 0 | 1 | 0 |
| Vomiting | 0 | 1 | 0 |
| Dehydration | 0 | 1 | 0 |
| Depression | 0 | 1 | 0 |
| Somnolence | 0 | 1 | 0 |
| Orthostasis | 1 | 0 | 0 |
| Rash | 1 | 0 | 0 |
| Hypokalemia | 0 | 1 | 0 |
| Hyperkalemia | 0 | 1 | 0 |
| ALT elevation | 0 | 2 | 0 |
| AST elevation | 0 | 1 | 1 |
| Pancreatitis | 0 | 1 | 0 |
| Pneumonia | 0 | 0 | 1 |
| Acidosis | 0 | 0 | 1 |
| Urinary tract infection | 0 | 1 | 0 |
| Sepsis | 0 | 0 | 1 |
| Pleural effusion | 0 | 0 | 1 |
| Sinusitis | 0 | 1 | 0 |
| Cardiac disorders | 0 | 1 | 0 |